Opinion|Videos|August 22, 2024
Updates from EHA 2024: Review of PERSEUS and IsKIA
Author(s)Rafael Fonseca, MD, Binod Dhakal, MD, MS
Multiple myeloma specialists analyze recent findings presented at EHA 2024, offering expert perspectives on the PERSEUS and IsKIA clinical trials and their implications for patient care.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Please briefly review updates and discuss the clinical implications from the trials.
Advertisement
Related to this article
Data from the phase 3 CERVINO trial support the application for etentamig as a treatment for adults with relapsed or refractory multiple myeloma.
The MagnetisMM-32 trial may support elranatamab as an important option for those whose disease has progressed following anti-CD38 therapy and lenalidomide.
In the phase 1/2 Bela-DRd study, over 90% of patients responded to belantamab mafodotin plus daratumumab, lenalidomide, and dexamethasone.
Matthew J. Frigault, MD, and Adam D. Cohen, MD, discuss guidelines, 5-year data, sequencing, and referral practice for cellular therapy in multiple myeloma.
Experts highlight updated findings from CARTITUDE-2, how to mitigate late toxicities, and other key considerations in the modern multiple myeloma landscape.
Erik Bengtsen, MD, discussed meaning-centered therapy at the bedside, framing psychiatry referrals, and a more humanistic approach to care.
Advertisement
Advertisement
Trending on CancerNetwork
1
Sac-TMT Improves Survival vs Chemotherapy in Pretreated Endometrial Cancer
2
Pembrolizumab Improves PFS Over Chemo in dMMR Endometrial Cancer
3
Cemiplimab Shows Real-World Efficacy in Advanced NSCLC Study
4
ctDNA Clearance Tracks With Survival on Pembrolizumab in HPV-Negative HNSCC
5